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820-2 Risk of Cardiovascular Disease in US Persons With 
Metabolic Risk Factors, Diabetes, and Elevated C-
Reactive Protein
Shaista Malik, Nathan Wong, Stanley Franklin, Jose Pio, Roland Chen, Carol Fairchild, 
University of California, Irvine, CA, Bristol-Myers Squibb Pharmaceutical Research 
Institute, Princeton, NJ
Background: We evaluated in U.S. persons the relationship of metabolic syndrome
(MetS) risk factors (RF) and diabetes and the likelihood of having cardiovascular disease
(CVD), and the potential impact of C-reactive protein (CRP) on this relationship.
Methods: We utilized data collected from participants of the Third National Health and
Nutrition Examination Survey on 6,451 subjects (weighted to a US. Population of 70 mil-
lion) aged 20 and over, who had measures of CRP, high density lipoprotein cholesterol
(HDL-C), triglycerides, blood glucose, blood pressure, and waist circumference. Persons
were classified according to number of MetS RF (0, 1, or 2), having MetS (but without
diabetes) requiring three or more of the criteria for MetS, according to National Choles-
terol Education Program criteria, or diabetes. Those with CRP levels of > 3 mg/l were
classified as having high CRP.
Results: The risk factor-adjusted odds ratios are shown in the table below. From the inter-
action term of CRP group with diabetes (p=0.03) and in analysis stratified by CRP levels,
there was evidence of further increases in odds for CVD in those with high CRP levels
and diabetes.
Conclusions: The odds for cardiovascular disease are substantially elevated once 2 MetS
RF are present, and is highest in those with diabetes. CRP levels are an independent risk
factor for CVD. The risk of cardiovascular disease is enhanced in persons with diabetes
with high CRP levels. 
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820-3 Nonhigh-Density Lipoprotein Cholesterol per National 
Cholesterol Education Panel and Advanced Lipoprotein 
Analysis: Correlation and Relationship to Premature 
Coronary Artery Disease
Kwame Osei Akosah, Ana Mari Schaper, Vicki Lynn McHugh, Sharon Ione Barnhart, 
Patricia A. Perlock, Troy Anthony Haider, Michelle Ann Mathiason, Gundersen Lutheran 
Health System, La Crosse, WI
Background: Overlap exists with LDL cholesterol levels between subjects with coronary
heart disease (CHD) versus those without, and studies suggest apolipoprotein–B (APO-
B) is a better risk predictor. NCEP has designated non-HDL cholesterol as a surrogate
for APO-B. Advanced lipoprotein analysis (NMR) measures atherogenic lipoproteins, but
correlations with non-HDL cholesterol as per NCEP are not well known.
Objectives: Evaluate correlations between non-HDL cholesterol as per NCEP and VLDL
plus LDL particles concentration (PRT), and determine relationships with angiographic
coronary artery disease (CAD).
Methods: 254 subjects (55% women ) undergoing elective coronary angiograms pro-
spectively enrolled. Exclusion criteria: statin therapy, known CAD and age (men > 55,
women > 65). Non-HDL cholesterol was defined as: 1) NCEP (total cholesterol - HDL); 2)
cholesterol by NMR (LDL + IDL +VLDLchol); and 3) atherogenic particles (LDL + VLDL).
Results: 76 subjects (30%) had CAD (<50 % stenosis) on angiogram. Mean values of
total cholesterol (196 mg/dL), LDL (122 mg/dL), HDL (51 mg/dL) and triglylcerides (147
mg/dL) were optimal. Mean values for non-HDL as follows: NCEP 144 mg/dL, NMR cho-
lesterol 237 mg/dL, and PRT 1435 nmol/L. Subjects with CAD had significantly higher
values for VLDL triglycerides (p = 0.003), VLDL PRT (p = 0.01) and LDL PRT (p = 0.008).
There was a strong correlation of non-HDL cholesterol per NCEP with atherogenic parti-
cles (r = .93; p>0.001), as well as the sum of LDL + IDL + VLDL chol (r = .6; p>0.001).
Univariate analysis revealed that individuals in the 4th quartile per NCEP (total choles-
terol - HDL) had an odds ratio of 2.6 for CAD (CI: 1.2-5.9) versus 3.3 (CI: 1.5-7.1) for
NMR cholesterol and 4.2 (CI: 1.9-9.6) for atherogenic particles. Multivariate analysis
revealed that non-HDL cholesterol (LDL + IDL + VLDLchol) to be the best predictor (OR:
2.2;CI:1.1-4.7).
Conclusion: Non-HDL cholesterol (total cholesterol - HDL) by NCEP correlates strongly
with atherogenic particle count and with non-HDL determined from VLDL cholesterol
plus LDL and IDL. Non-HDL cholesterol may explain why some subjects with low LDL
benefit from therapy.
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820-4 Effective Reduction of Novel Atherogenic Low-Density 
Lipoprotein Subfraction by Atorvastatin in Patients With 
Hypercholesterolemia
Chu-Huang Chen, Patricia W. Pace, Nell D. Karakoc, Jonathan Lu, Hsin-Hung Chen, 
Philip D. Henry, Henry J. Pownall, John P. Foreyt, Christie M. Ballantyne, Chao-Yuh Yang, 
Baylor College of Medicine, Houston, TX
Background:
A highly electronegative and mildly oxidized subfraction of human plasma low-density
lipoprotein (LDL), designated L5, induces profound apoptosis in vascular endothelial
cells (EC) and increases monocyte adhesion to EC. Given these proatherogenic proper-
ties, we sought a pharmacologic means for the reduction of plasma L5 levels.
Methods:
LDL from 8 asymptomatic, hypercholesterolemic (HC) patients (LDL-C = 189 ± 18 mg/
dL) and 8 sex- and age-matched control subjects (LDL-C = 105 ± 4 mg/dL) was sepa-
rated into subfractions on the basis of charge using ion exchange chromatography. After
3 months' treatment with atorvastatin (10–20 mg/day), LDL from the HC patients was
again analyzed. The percentage of LDL in the L5 subfraction was calculated as the ratio
L5 protein/total LDL protein x 100%.
Results:
At baseline, the L5 percentage was 0.86 ± 0.18% in the HC patients and 0.05 ± 0.06% in
the control subjects (P < 0.001). Plasma concentrations of homocysteine, C-reactive pro-
tein, glucose, insulin, and hemoglobin A1c were all within normal limits and not different
between groups. L5 from HC patients induced apoptosis and reduced DNA synthesis in
cultured bovine aortic EC. These changes were accompanied by reduced protein and
mRNA levels of fibroblast growth factor 2, a potent mitogenic and antiapoptotic protein.
The other subfractions, L1–L4, had no effect. Yields of L5 from the control subjects were
too low for further studies. After treatment with atorvastatin, the L5 percentage in the HC
patients decreased by 84% to 0.15 ± 0.08% (P < 0.01). The LDL-C concentration
decreased by 36% to 120 ± 16 mg/dL (P < 0.05). The non-HDL-C/HDL-C ratio decreased
by 42%, from 4.2 ± 1.1 at baseline to 2.4 ± 0.8 after treatment (P < 0.05).
Conclusion:
A highly electronegative subfraction of LDL, L5, which induces apoptosis and inflamma-
tion, is a potential atherogenic risk factor independent of insulin resistance and plasma
concentrations of homocysteine and C-reactive protein. In HC patients treated with atorv-
astatin, the reduction in L5 (84%) was greater than the reduction in LDL-C (36%). These
findings strongly suggest that L5 is a novel therapeutic target, which can be effectively
reduced by atorvastatin.
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820-5 Once-Daily Niacin Extended-Release/Lovastatin 
Combination Is Effective and Safe for Treatment of 
Dyslipidemia Associated With Metabolic Syndrome
Mark E. McGovern, Carolin M. Malott, Phillip D. Simmons, Eric J. Stanek, Kos Division of 
Medical Affairs, Weston, FL
Background: Metabolic syndrome is increasingly prevalent worldwide. While low-density
lipoprotein cholesterol (LDL-C) is the primary target of therapy, metabolic syndrome is
associated with low high-density lipoprotein cholesterol (HDL-C) and elevated triglycer-
ides (TG). Niacin effectively raises HDL-C and reduces TG and lipoprotein (a) [Lp(a)].
Statins primarily lower LDL-C. We evaluated the effects of a niacin extended-release/lov-
astatin (ERNL) combination drug in patients with and without metabolic syndrome. We
hypothesized that ERNL would be similarly effective and safe in both patient groups.
Methods: This was a retrospective analysis of 757 dyslipidemic patients from an open-
label, multicenter, 52-week study of ERNL dosed initially as one 500/10 tablet (milligrams
niacin/milligrams lovastatin) once-nightly. The dose was escalated at monthly intervals to
2,000/40 at week 16. Thereafter the dose was stable. We defined metabolic syndrome
using current National Cholesterol Education Program criteria, substituting body mass
index >28 for waist circumference. Effects on lipids and safety (liver enzymes, fasting glu-
cose, and myopathy) were evaluated.
Results: Lipid results are shown. There were no differences between treatment groups
in the percent of patients with 3-fold increases in liver tests (<1% in each group) or
increases in glucose. No confirmed myopathy was reported.
Conclusion: We conclude that once-daily ERNL is effective and safe for patients with
metabolic syndrome.
Table: Weighted logistic regression examining relation of each disease/condition 
category (compared to those with no MetS risk factors), high CRP to cardiovascular 
disease (adjusted for age, gender, total cholesterol, and smoking)
Regression with entire sample Stratified regression by CRP levels
Low CRP < 3 mg/l High CRP > 3 
mg/l
Condition N=6451 Odds ratio, 
95% CI
p-value Odds ratio, 95% 
CI
p-value Odds ratio, 
95% CI
p-
value
0 MetS RF 
(reference 
group)
1591 (24.7%) --- --- --- ---
1 MetS RF 1658 (25.7%) 2.22 (1.08-
4.55)
.03 2.61 (1.04-6.54) .04 1.40 (.48-
4.03)
.54
2 MetS RF 1356 (21.0%) 4.37 (2.19-
8.72)
<.001 4.81 (1.96-
11.82)
<.001 3.26 (1.23-
8.65)
.02
MetS (3-5 RF) 1223 (19.0%) 3.99 (2.02-
7.87)
<.001 4.62 (2.00-
10.66)
<.001 2.93 (1.04-
8.30)
.04
Diabetes 623 (9.7%) 7.04 (3.59-
13.79)
<.001 5.65 (2.34-
13.68)
<.001 7.07 (2.65-
18.84)
<.001
CRP < 3mg/l > 
3 mg/l
4346 (67.4%) 
2105 (32.6%)
1.0 1.58 
(1.15-2.17)
<.001 --- ---
